Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 7/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.54 |
| ▸ | AXL | P30530 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.51 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | ROS1 | P08922 | 3/20 | 0.46 |
| ▸ | MARK3 | P27448 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652391 | 0.89 | CDK8 (0.56) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL29652420 | 0.85 | PLK4 (0.58) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL28502063 | 0.85 | CDK8 (0.52) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL30376973 | 0.85 | RIPK1 (0.57) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL30376196 | 0.84 | MAP3K11 (0.66) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL29652315 | 0.84 | RIPK1 (0.52) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| Hydrochloric Acid SCHEMBL30313452 | 0.83 | MAP3K11 (0.65) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL4831501 | 0.78 | CDK8 (0.81) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL30597879 | 0.78 | RIPK1 (0.49) | CDK8ROCK2AXLPIK3CDPIK3CA | |
| SCHEMBL30945083 | 0.78 | ROCK2 (0.50) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | CDK8 69/4885ROCK2 343/4885AXL 1476/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CDK8 69/4885ROCK2 343/4885AXL 1476/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CDK8 69/4885ROCK2 343/4885AXL 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.